AIA Partners with VitalLife, Bumrungrad Hospital Network, to Launch Longevity Service in January 2027

The Stock Exchange of Thailand has ordered SPTX, or SPTX, to clarify details of its 1,195 million baht investment in Rasmipoom Beauty Anti-Aging Co., Ltd., requiring the clarification to be submitted through the exchange's disclosure system by October 5, 2026, and the company's board and audit committee to give their opinions by October 12, 2026, while warning investors to study the information carefully before deciding to invest. On September 15, 2026, the SPTX board resolved to invest 1,195 million baht in the target company, representing a 92% shareholding, by purchasing shares from Rasmipoom Holding (Thailand) Co., Ltd. and Rasmipoom Holding (Hong Kong) Co., Ltd., both wholly owned by Mr. Rasmipoom Sumetheewit. The transaction qualifies as a significant acquisition of assets, with a maximum transaction size of 50.52% of total assets, and is a connected transaction, since Mr. Rasmipoom is a major shareholder and vice chairman of SPTX; after the transaction his SPTX stake will rise from 21% to 43%. As of June 30, 2026, the target company had assets of 306 million baht, shareholders' equity of 187 million baht, and net profit of 32 million baht for the six-month period. After the investment, the sellers will hold 8% of the target company and have the right to nominate at least 2 of 5 directors, with approval of major transactions requiring the consent of the seller group. The company will transfer the land and buildings that house two clinic branches and constitute its main assets back to the sellers and enter into a leaseback agreement to continue operating the business, and the sellers have agreed to a performance guarantee for five years after SPTX acquires the business, covering the expansion of no fewer than 9 branches. The exchange has asked SPTX to clarify five additional points: the timeline of Mr. Rasmipoom's shareholding and preparations for the investment; the rationale and necessity for transferring the land and buildings to the sellers and leasing them back, which will create significant related-party transactions in the future; information supporting the pricing criteria and key assumptions, including whether the land and buildings are included in the price; the proportion of SPTX's assets or operating revenue that will change and the reasonableness of the management authority and board structure at the target company; and the opinions of the board and audit committee on the reasonableness of control rights, the trading conditions, the adequacy of the investment funds, the results of the business due diligence, and the action plan if operating results or branch expansion do not meet the sellers' guarantees.

HL is pressing ahead with full force to expand its customer base in the second half of 2026 by opening a new iCare branch at Phutthamonthon Sai 4, while accelerating the development of innovative products under the Prime brand, a line of health-care supplements including Prime Immuliv, Prime G3 and an absorption-enhancing product, as well as skin-care products and herbal products under the Q brand that have won international awards. The company is also moving into the Pet Health market in line with the pet humanization trend by sourcing and distributing supplements, vitamins and medicines for pets. Meanwhile, PTG has received the Human Rights Awards 2026 at the outstanding level in the large business organisation category for the second consecutive year. TMAN, for its part, has opened the Heaven Herb factory in Pathum Thani province, showcasing the potential of a production base driven by modern technology, with a target of creating 15 new products within five years to meet global demand and the growing longevity trend, while continuing to transform the factory with an investment budget of 50 million baht per year to help drive Thailand toward becoming a Global Wellness Hub.